SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Michel P. Lamure · Study

Home/Author

Michel P. Lamure

6 works· latest 2016· 3 institutionscluster: provisionalORCID 0009-0008-6011-6052

h-index6

i106

Citations437

Works here6

02

12

13

14

16

Most cited in this library

The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma2016 · 115 citations
Methodological considerations in cost of illness studies on Alzheimer disease2012 · 90 citations
Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature2013 · 65 citations
Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project2014 · 64 citations
Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications2014 · 55 citations

Works

6 shown

The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma

Neuro-Oncology·2016·6 authors·Open access

115citations

Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project

PharmacoEconomics·2014·9 authors

64citations

Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications

Journal of Market Access & Health Policy·2014·4 authors·Open access

55citations

Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature

Journal of Market Access & Health Policy·2013·4 authors·Open access

65citations

Methodological considerations in cost of illness studies on Alzheimer disease

Health Economics Review·2012·10 authors·Open access

90citations

Limitations of the Methods Used for Calculating Quality-Adjusted Life-Year Values

PharmacoEconomics·2002·6 authors

48citations